• Redefining
    the posibilities
  • Facilitating
    cell therapy
  • Clients
    choose us
Latest News

Novartis announces an exclusive global licensing and research collaboration with Regenerex
New research recently published by the hospital suggests organ transplant recipients may not require anti-rejection medication in the future.
Rob requires no anti-rejection medication more than two years after a combination kidney/stem cell transplant in a clinical trial NSCF funds
More News
Who are we?
Regenerex, LLC was incorporated in 2002 in Delaware. Regenerex is a biopharmaceutical company based in Louisville Kentucky for production of the company’s proprietary FCRx platform therapy. The hematopoietic stem cell-based immunological tolerance protocol is in the final stages of a
successful FDA Phase II clinical trial in living donor kidney transplant recipients that has resulted in graft survival without the need for lifelong immunosuppression.
Read more
Latest Projects